Abstract
The number of targetable genomic alterations in non-squamous non-small cell lung cancer (NS-NSCLC) patients increased these last few years, while the tissue material reduced in size. Therefore, molecular pathologists are facing challenges to maintain a strategy allowing a rapid diagnosis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
